Santhera leaps on detailed DMD data

Santhera Pharmaceuticals Holding AG (SIX:SANN) jumped CHF13.94 (163%) to CHF22.50 on Thursday after presenting additional data from the Phase III DELOS trial of the company's Catena idebenone to treat Duchenne muscular dystrophy (DMD) at BioCentury's BioEquity Europe meeting in Amsterdam. In the 64-patient, double-blind trial, oral Catena led to a 3.1% mean decline in peak expiratory flow from baseline to week 52, the primary endpoint, as measured by hospital-based spirometry assessments vs. a 9% decline for patients receiving placebo (p=0.04). Santhera reported that Catena met the primary endpoint earlier this month, but did not provide detailed data. The stock has skyrocketed CHF18.75 (500%) since May 12, the day before Santhera reported Catena met the primary endpoint in DELOS (see BioCentury Extra, May 13). ...